Potential Therapeutic Effects of Empagliflozin Through Elevated Plasma Citrulline Levels in Heart Failure With Preserved Ejection Fraction
Empagliflozin significantly increased citrulline levels in HFpEF patients. Although further studies are needed, it would be intriguing if this metabolite change were related to the cardiovascular protective effects of empagliflozin.
Authors
- Masashi Yokoi (ORCID: https://orcid.org/0000-0002-4952-9568)
- Sayuri Yamabe
- Yu Kawada
- Yoshiro Tsuruta (ORCID: https://orcid.org/0000-0001-8116-2236)
- Yoshihiro Seo (ORCID: https://orcid.org/0000-0003-4319-3124)
- Toshihiko Goto (ORCID: https://orcid.org/0000-0001-7132-2806)
- Yasuhiro Shintani
- Shohei Kikuchi (ORCID: https://orcid.org/0000-0002-0961-6253)
- Shuichi Kitada (ORCID: https://orcid.org/0000-0002-9824-9001)
- Tatsuya Mizoguchi (ORCID: https://orcid.org/0000-0002-1305-1400)
- Tsuyoshi Ito (ORCID: https://orcid.org/0000-0002-1871-0954)
- Kento Mori
Institutions
- Nagoya City University (JP)
Publication Details
- Journal
- Circulation Journal
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1253/circj.cj-24-0953
- Citations
- 1
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 2.01